

Mohammed Lamorde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8243282/publications.pdf>

Version: 2024-02-01

75
papers

1,371
citations

361045

20
h-index

414034

32
g-index

84
all docs

84
docs citations

84
times ranked

1958
citing authors

#	ARTICLE	IF	CITATIONS
1	Medicinal plants used by traditional medicine practitioners for the treatment of HIV/AIDS and related conditions in Uganda. <i>Journal of Ethnopharmacology</i> , 2010, 130, 43-53.	2.0	121
2	Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. <i>Clinical Infectious Diseases</i> , 2016, 62, 675-682.	2.9	75
3	Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e332-e339.	2.1	75
4	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1772-1777.	1.3	69
5	Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). <i>PLoS Medicine</i> , 2019, 16, e1002895.	3.9	58
6	Dolutegravir-associated hyperglycaemia in patients with HIV. <i>Lancet HIV</i> , 2020, 7, e461-e462.	2.1	58
7	Optimizing antimicrobial use: challenges, advances and opportunities. <i>Nature Reviews Microbiology</i> , 2021, 19, 747-758.	13.6	51
8	Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis. <i>BMC Health Services Research</i> , 2016, 16, 304.	0.9	49
9	Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV. <i>Drug Safety</i> , 2016, 39, 1053-1072.	1.4	41
10	Antimicrobial Drug Resistance in Blood Culture Isolates at a Tertiary Hospital, Uganda. <i>Emerging Infectious Diseases</i> , 2018, 24, 174-175.	2.0	35
11	Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. <i>Clinical Infectious Diseases</i> , 2018, 67, 708-716.	2.9	34
12	Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004568.	1.3	34
13	Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1013-1019.	1.3	30
14	Cost-effectiveness of Antivenoms for Snakebite Envenoming in Nigeria. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e3381.	1.3	29
15	Impact of a mobile phone-based interactive voice response software on tuberculosis treatment outcomes in Uganda (CFL-TB): a protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 391.	0.7	29
16	Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-6.	0.3	25
17	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. <i>PLoS ONE</i> , 2020, 15, e0227458.	1.1	25
18	Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 345-350.	0.9	23

#	ARTICLE	IF	CITATIONS
19	Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. <i>Aids</i> , 2013, 27, 961-965.	1.0	23
20	Efavirenz-but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant. <i>Journal of the International AIDS Society</i> , 2014, 17, 19484.	1.2	23
21	Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1060, 300-307.	1.2	23
22	An Interactive Voice Response Software to Improve the Quality of Life of People Living With HIV in Uganda: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2021, 9, e22229.	1.8	23
23	Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 180-183.	1.3	21
24	A Cross-Cutting Approach to Surveillance and Laboratory Capacity as a Platform to Improve Health Security in Uganda. <i>Health Security</i> , 2018, 16, S-76-S-86.	0.9	21
25	Safer primary healthcare facilities are needed to protect healthcare workers and maintain essential services: lessons learned from a multicountry COVID-19 emergency response initiative. <i>BMJ Global Health</i> , 2021, 6, e005833.	2.0	21
26	Antenatal Syphilis Screening Using Point-Of-Care Testing in Low- and Middle-Income Countries in Asia and Latin America: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2015, 10, e0127379.	1.1	20
27	Acceptability of a Mobile Phone Support Tool (Call for Life Uganda) for Promoting Adherence to Antiretroviral Therapy Among Young Adults in a Randomized Controlled Trial: Exploratory Qualitative Study. <i>JMIR MHealth and UHealth</i> , 2021, 9, e17418.	1.8	17
28	Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
29	Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1004-1012.	1.3	15
30	Implementation of a standardised and quality-assured enhanced gonococcal antimicrobial surveillance programme in accordance with WHO protocols in Kampala, Uganda. <i>Sexually Transmitted Infections</i> , 2021, 97, 312-316.	0.8	15
31	Antimicrobial Resistance of Sterile Site Infections in Sub-Saharan Africa: A Systematic Review. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx209.	0.4	14
32	The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. <i>Tuberculosis</i> , 2018, 108, 77-82.	0.8	14
33	Pharmacokinetics, Safety/tolerability, and Efficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). <i>Trials</i> , 2020, 21, 181.	0.7	14
34	Antimicrobial Resistance of Neisseria Gonorrhoeae in a Newly Implemented Surveillance Program in Uganda: Surveillance Report. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e17009.	1.2	14
35	Estimating the cost and cost-effectiveness for obstetric fistula repair in hospitals in Uganda: a low income country. <i>Health Policy and Planning</i> , 2018, 33, 999-1008.	1.0	13
36	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3003-3010.	1.3	13

#	ARTICLE	IF	CITATIONS
37	The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 450-457.	2.3	13
38	Steady-State Pharmacokinetics of Lopinavir Plus Ritonavir When Administered Under Different Meal Conditions in HIV-Infected Ugandan Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 295-298.	0.9	12
39	Implementation of the World Health Organization Global Antimicrobial Resistance Surveillance System in Uganda, 2015-2020: Mixed-Methods Study Using National Surveillance Data. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e29954.	1.2	12
40	Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	11
41	Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DOLPHIN-1. <i>Clinical Infectious Diseases</i> , 2021, 73, e1200-e1207.	2.9	11
42	Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique. <i>BMC Infectious Diseases</i> , 2014, 14, 473.	1.3	10
43	The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007787.	1.3	10
44	Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. <i>BMC Infectious Diseases</i> , 2021, 21, 1154.	1.3	10
45	Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 20-29.	1.3	10
46	Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. <i>BMJ Open</i> , 2017, 7, e014679.	0.8	9
47	Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black African Patients in South Africa and Uganda. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1564-1574.	2.3	8
48	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 135-138.	1.3	7
49	Cost-effectiveness of expanding childhood routine immunization against <i>Neisseria meningitidis</i> serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt. <i>PLoS ONE</i> , 2017, 12, e0188595.	1.1	7
50	T-Cell Homeostatic Imbalance in Placentas From Women With Human Immunodeficiency Virus in the Absence of Vertical Transmission. <i>Journal of Infectious Diseases</i> , 2021, 224, S670-S682.	1.9	6
51	A Lower Dose of Efavirenz Can Be Co-administered With Rifampicin and Isoniazid in Tuberculosis Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz035.	0.4	5
52	Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study. <i>AIDS Research and Therapy</i> , 2019, 16, 39.	0.7	5
53	The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women. <i>Drug Safety</i> , 2020, 43, 1133-1140.	1.4	5
54	Antiretroviral drugs for prevention of mother-to-child transmission. <i>Aids</i> , 2014, 28, 2551-2563.	1.0	4

#	ARTICLE	IF	CITATIONS
55	An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir. <i>BMC Infectious Diseases</i> , 2019, 19, 280.	1.3	4
56	Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda. <i>Oxford Medical Case Reports</i> , 2019, 2019, omy132.	0.2	4
57	Pre-positioned Outbreak Research: The Joint Medical Emerging Diseases Intervention Clinical Capability Experience in Uganda. <i>Health Security</i> , 2020, 18, 114-124.	0.9	4
58	Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. <i>Bioanalysis</i> , 2018, 10, 1933-1945.	0.6	3
59	Implementing routine physical function screening among elderly HIV-positive patients in Uganda. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1467-1470.	0.6	3
60	Calcaneal Quantitative Ultrasonography and Urinary Retinol-Binding Protein in Antiretroviral-Treated Patients With Human Immunodeficiency Virus in Uganda: A Pilot Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 263-272.	1.9	3
61	Evaluation of the Management of Patients with Detectable Viral Load after the Implementation of Routine Viral Load Monitoring in an Urban HIV Clinic in Uganda. <i>AIDS Research and Treatment</i> , 2019, 2019, 1-5.	0.3	3
62	Blood Culture Testing Outcomes among Non-Malarial Febrile Children at Antimicrobial Resistance Surveillance Sites in Uganda, 2017-2018. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 71.	0.9	2
63	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). <i>Trials</i> , 2021, 22, 831.	0.7	2
64	Willingness to pay for an mHealth anti-retroviral therapy adherence and information tool: Transitioning to sustainability, Call for life randomised study experience in Uganda. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 52.	1.5	2
65	Antiretroviral therapy in developing countries: pharmacologic considerations. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 252-257.	1.5	1
66	Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting. <i>Hepatology, Medicine and Policy</i> , 2018, 3, 3.	1.7	1
67	Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine". <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	1
68	In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. <i>HIV Medicine</i> , 2021, 22, 898-906.	1.0	1
69	Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. <i>Wellcome Open Research</i> , 2018, 3, 111.	0.9	0
70	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
71	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
72	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0

#	ARTICLE	IF	CITATIONS
73	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
74	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
75	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0